Torrent Pharmaceuticals Limited (TORNTPHARM.NS)
INR 3325.1
(-0.22%)
INR 3325.1
(-0.22%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 82.05 Billion INR | -6.91% |
| 2022 | 88.14 Billion INR | 23.33% |
| 2021 | 71.46 Billion INR | -13.24% |
| 2020 | 82.37 Billion INR | -10.6% |
| 2019 | 92.14 Billion INR | -1.94% |
| 2018 | 93.96 Billion INR | -2.33% |
| 2017 | 96.2 Billion INR | 66.61% |
| 2016 | 57.74 Billion INR | 2.67% |
| 2015 | 56.24 Billion INR | 3.76% |
| 2014 | 54.2 Billion INR | 71.14% |
| 2013 | 31.66 Billion INR | 34.16% |
| 2012 | 23.6 Billion INR | 25.81% |
| 2011 | 18.76 Billion INR | 23.08% |
| 2010 | 15.24 Billion INR | 34.41% |
| 2009 | 11.34 Billion INR | 11.57% |
| 2008 | 10.16 Billion INR | 34.42% |
| 2007 | 7.56 Billion INR | 19.15% |
| 2006 | 6.34 Billion INR | 6.84% |
| 2005 | 5.94 Billion INR | 50.36% |
| 2004 | 3.95 Billion INR | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 75.84 Billion INR | 210.62% |
| 2024 Q1 | -68.56 Billion INR | -183.56% |
| 2023 FY | 82.05 Billion INR | -6.91% |
| 2023 Q2 | 80.37 Billion INR | 0.0% |
| 2023 Q1 | - INR | -100.0% |
| 2023 Q4 | 82.05 Billion INR | 0.0% |
| 2023 Q3 | - INR | -100.0% |
| 2022 Q1 | - INR | -100.0% |
| 2022 Q3 | - INR | -100.0% |
| 2022 Q2 | 71.28 Billion INR | 0.0% |
| 2022 FY | 88.14 Billion INR | 23.33% |
| 2022 Q4 | 88.14 Billion INR | 0.0% |
| 2021 Q1 | - INR | -100.0% |
| 2021 Q4 | 71.46 Billion INR | 0.0% |
| 2021 Q2 | 74.64 Billion INR | 0.0% |
| 2021 Q3 | - INR | -100.0% |
| 2021 FY | 71.46 Billion INR | -13.24% |
| 2020 Q2 | 89.41 Billion INR | 0.0% |
| 2020 Q1 | - INR | -100.0% |
| 2020 Q4 | 82.37 Billion INR | 0.0% |
| 2020 Q3 | - INR | -100.0% |
| 2020 FY | 82.37 Billion INR | -10.6% |
| 2019 Q3 | - INR | -100.0% |
| 2019 Q2 | 89.03 Billion INR | 0.0% |
| 2019 Q1 | - INR | -100.0% |
| 2019 FY | 92.14 Billion INR | -1.94% |
| 2019 Q4 | 92.14 Billion INR | 0.0% |
| 2018 Q3 | - INR | -100.0% |
| 2018 Q1 | - INR | -100.0% |
| 2018 FY | 93.96 Billion INR | -2.33% |
| 2018 Q4 | 93.96 Billion INR | 0.0% |
| 2018 Q2 | 103.15 Billion INR | 0.0% |
| 2017 FY | 96.2 Billion INR | 66.61% |
| 2017 Q4 | 96.2 Billion INR | 0.0% |
| 2017 Q3 | - INR | -100.0% |
| 2017 Q2 | 55.06 Billion INR | 0.0% |
| 2017 Q1 | - INR | -100.0% |
| 2016 FY | 57.74 Billion INR | 2.67% |
| 2016 Q1 | - INR | -100.0% |
| 2016 Q2 | 61.67 Billion INR | 0.0% |
| 2016 Q3 | - INR | -100.0% |
| 2016 Q4 | 57.74 Billion INR | 0.0% |
| 2015 Q1 | - INR | -100.0% |
| 2015 FY | 56.24 Billion INR | 3.76% |
| 2015 Q4 | 56.24 Billion INR | 0.0% |
| 2015 Q2 | 61.34 Billion INR | 0.0% |
| 2015 Q3 | - INR | -100.0% |
| 2014 Q2 | 48.34 Billion INR | 0.0% |
| 2014 Q1 | - INR | -100.0% |
| 2014 FY | 54.2 Billion INR | 71.14% |
| 2014 Q4 | 54.2 Billion INR | 0.0% |
| 2014 Q3 | - INR | -100.0% |
| 2013 Q1 | - INR | -100.0% |
| 2013 Q2 | 30.28 Billion INR | 0.0% |
| 2013 Q3 | - INR | -100.0% |
| 2013 Q4 | 31.66 Billion INR | 0.0% |
| 2013 FY | 31.66 Billion INR | 34.16% |
| 2012 Q4 | 23.6 Billion INR | 0.0% |
| 2012 FY | 23.6 Billion INR | 25.81% |
| 2012 Q3 | - INR | 0.0% |
| 2011 FY | 18.76 Billion INR | 23.08% |
| 2011 Q4 | 18.76 Billion INR | 0.0% |
| 2010 FY | 15.24 Billion INR | 34.41% |
| 2009 FY | 11.34 Billion INR | 11.57% |
| 2008 FY | 10.16 Billion INR | 34.42% |
| 2007 FY | 7.56 Billion INR | 19.15% |
| 2006 FY | 6.34 Billion INR | 6.84% |
| 2005 FY | 5.94 Billion INR | 50.36% |
| 2004 FY | 3.95 Billion INR | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Morepen Laboratories Limited | 4.45 Billion INR | -1739.773% |
| Innova Captab Limited | 4.89 Billion INR | -1574.534% |
| Brooks Laboratories Limited | 248.6 Million INR | -32904.694% |
| Eris Lifesciences Limited | 38.26 Billion INR | -114.409% |
| Themis Medicare Limited | 1.88 Billion INR | -4246.995% |
| Orchid Pharma Limited | 3.84 Billion INR | -2034.452% |
| Albert David Limited | 1.15 Billion INR | -7034.131% |
| Alembic Limited | 1.43 Billion INR | -5629.349% |
| Alkem Laboratories Limited | 48.6 Billion INR | -68.81% |
| Alembic Pharmaceuticals Limited | 16.27 Billion INR | -404.185% |
| Bafna Pharmaceuticals Limited | 652.27 Million INR | -12478.973% |
| Bajaj HealthCare Limited | 4.86 Billion INR | -1585.612% |
| Biofil Chemicals and Pharmaceuticals Limited | 288.79 Million INR | -28310.763% |
| FDC Limited | 3.7 Billion INR | -2112.063% |
| Glenmark Life Sciences Limited | 5.18 Billion INR | -1483.702% |
| Gufic Biosciences Limited | 5.59 Billion INR | -1365.228% |
| Hester Biosciences Limited | 3.59 Billion INR | -2182.514% |
| Hikal Limited | 12.99 Billion INR | -531.402% |
| Ind-Swift Laboratories Limited | 2.28 Billion INR | -3483.813% |
| Ind-Swift Limited | 13.45 Billion INR | -509.903% |
| IOL Chemicals and Pharmaceuticals Limited | 6.32 Billion INR | -1196.434% |
| Ipca Laboratories Limited | 33.74 Billion INR | -143.163% |
| Jagsonpal Pharmaceuticals Limited | 296.76 Million INR | -27548.605% |
| Jubilant Pharmova Limited | 61.27 Billion INR | -33.907% |
| Kilitch Drugs (India) Limited | 643.88 Million INR | -12642.998% |
| Laurus Labs Limited | 42.71 Billion INR | -92.089% |
| Lincoln Pharmaceuticals Limited | 1.07 Billion INR | -7535.79% |
| Mangalam Drugs & Organics Limited | 1.97 Billion INR | -4051.675% |
| Medico Remedies Limited | 438.24 Million INR | -18622.447% |
| Nectar Lifesciences Limited | 11.21 Billion INR | -631.408% |
| Procter & Gamble Health Limited | 2.56 Billion INR | -3103.576% |
| RPG Life Sciences Limited | 1.38 Billion INR | -5844.791% |
| Sigachi Industries Limited | 2.53 Billion INR | -3141.462% |
| Solara Active Pharma Sciences Limited | 14.09 Billion INR | -482.254% |
| Sun Pharmaceutical Industries Limited | 183.56 Billion INR | 55.303% |
| Suven Pharmaceuticals Limited | 2.03 Billion INR | -3933.469% |
| Unichem Laboratories Limited | 8.06 Billion INR | -916.823% |
| Vaishali Pharma Limited | 371.16 Million INR | -22006.191% |
| Venus Remedies Limited | 1.39 Billion INR | -5791.011% |
| Wanbury Limited | 3.15 Billion INR | -2500.208% |
| Windlas Biotech Limited | 1.76 Billion INR | -4554.791% |
| ZIM Laboratories Limited | 2.08 Billion INR | -3843.267% |
| Aarti Pharmalabs Limited | 8.25 Billion INR | -894.461% |
| Aarti Drugs Limited | 11.5 Billion INR | -613.23% |
| Lupin Limited | 96.23 Billion INR | 14.742% |
| Sakar Healthcare Limited | 1.26 Billion INR | -6394.997% |
| Aurobindo Pharma Limited | 152.2 Billion INR | 46.093% |
| Divi's Laboratories Limited | 18.99 Billion INR | -332.07% |
| AstraZeneca Pharma India Limited | 3.66 Billion INR | -2141.124% |
| Mankind Pharma Limited | 23.87 Billion INR | -243.67% |
| Sequent Scientific Limited | 8.27 Billion INR | -891.631% |
| Neuland Laboratories Limited | 5.49 Billion INR | -1392.208% |
| J. B. Chemicals & Pharmaceuticals Limited | 10.7 Billion INR | -666.25% |
| Glenmark Pharmaceuticals Limited | 65.11 Billion INR | -26.016% |
| Zydus Lifesciences Limited | 71.79 Billion INR | -14.289% |
| Amrutanjan Health Care Limited | 783.82 Million INR | -10367.911% |
| Wockhardt Limited | 39.87 Billion INR | -105.794% |
| Bal Pharma Limited | 2.51 Billion INR | -3167.263% |
| Dr. Reddy's Laboratories Limited | 106.96 Billion INR | 23.295% |
| Bliss GVS Pharma Limited | 2.1 Billion INR | -3790.744% |
| Par Drugs and Chemicals Limited | 159.79 Million INR | -51248.324% |
| Caplin Point Laboratories Limited | 3.5 Billion INR | -2240.541% |
| Shilpa Medicare Limited | 12.93 Billion INR | -534.449% |
| Valiant Laboratories Limited | 1.05 Billion INR | -7653.286% |
| Ajanta Pharma Limited | 10.71 Billion INR | -666.085% |
| Aarey Drugs & Pharmaceuticals Limited | 1.72 Billion INR | -4664.29% |
| Granules India Limited | 22.95 Billion INR | -257.448% |
| Medicamen Biotech Limited | 940.36 Million INR | -8625.317% |
| Syncom Formulations (India) Limited | 1.16 Billion INR | -6941.643% |
| Piramal Enterprises Limited | 560.47 Billion INR | 85.361% |
| NATCO Pharma Limited | 10.53 Billion INR | -679.054% |
| Suven Life Sciences Limited | 148.62 Million INR | -55107.541% |
| Krebs Biochemicals & Industries Limited | 2.97 Billion INR | -2658.99% |
| Strides Pharma Science Limited | 37.68 Billion INR | -117.752% |
| Indoco Remedies Limited | 10.34 Billion INR | -693.344% |
| Alpa Laboratories Limited | 307.12 Million INR | -26615.768% |
| Lasa Supergenerics Limited | 541.92 Million INR | -15040.471% |
| Sun Pharma Advanced Research Company Limited | 3.89 Billion INR | -2007.683% |